February 20, 2018 10:08 AM EST

Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with antisense player Wave Life Sciences

John Carroll

Editor & Founder

→ Acorda $ACOR says that the FDA has finally accepted their application for Inbrija (CVT-301), putting their inhaled form of levodopa for Parkinson’s on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with antisense player Wave Life Sciences

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Acor­da gets a bad­ly need­ed PDU­FA date with the FDA on Parkin­son's drug; Take­da signs neu­ro­log­i­cal col­lab­o­ra­tion with an­ti­sense play­er Wave Life Sci­ences

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with antisense player Wave Life Sciences